

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)**Search Results -**

Term	Documents
PARTICLE.DWPI,EPAB,JPAB,USPT.	549938
PARTICLES.DWPI,EPAB,JPAB,USPT.	734503
(4 AND PARTICLE).USPT,JPAB,EPAB,DWPI.	7

Database: US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Refine Search:

L4 and (particle)

[Clear](#)**Search History**

Today's Date: 8/16/2001

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT,JPAB,EPAB,DWPI	L4 and (particle)	7	<u>L5</u>
USPT,JPAB,EPAB,DWPI	oxcarbazine	48	<u>L4</u>
USPT,JPAB,EPAB,DWPI	L2 and (particle ADJ size)	2	<u>L3</u>
USPT,JPAB,EPAB,DWPI	L1 and (particle)	2	<u>L2</u>
USPT,JPAB,EPAB,DWPI	oxacarbazine	2	<u>L1</u>

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)**Search Results -**

Term	Documents
PARTICLE.DWPI,EPAB,JPAB,USPT.	549938
PARTICLES.DWPI,EPAB,JPAB,USPT.	734503
SIZE.DWPI,EPAB,JPAB,USPT.	1863419
SISE.DWPI,EPAB,JPAB,USPT.	92
SISES.DWPI,EPAB,JPAB,USPT.	7
SIZES.DWPI,EPAB,JPAB,USPT.	370245
(2 AND (PARTICLE ADJ SIZE)).USPT,JPAB,EPAB,DWPI.	2

☐ US Patents Full-Text Database
☐ US Pre-Grant Publication Full-Text Database
☐ JPO Abstracts Database
☐ EPO Abstracts Database
☐ Derwent World Patents Index
☐ IBM Technical Disclosure Bulletins

Database:**Refine Search:**

L2 and (particle ADJ size)

Clear**Search History****Today's Date: 8/16/2001**

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT,JPAB,EPAB,DWPI	L2 and (particle ADJ size)	2	<u>L3</u>
USPT,JPAB,EPAB,DWPI	L1 and (particle)	2	<u>L2</u>
USPT,JPAB,EPAB,DWPI	oxacarbazepine	2	<u>L1</u>

Term	Documents
PARTICLE.DWPI,EPAB,JPAB,USPT.	549938
PARTICLES.DWPI,EPAB,JPAB,USPT.	734503
SIZE.DWPI,EPAB,JPAB,USPT.	1863419
SISE.DWPI,EPAB,JPAB,USPT.	92
SISES.DWPI,EPAB,JPAB,USPT.	7
SIZES.DWPI,EPAB,JPAB,USPT.	370245
(2 AND (PARTICLE ADJ SIZE)).USPT,JPAB,EPAB,DWPI.	2

Display

25

Documents, starting with Document:

2

Display Format:

REV

Change Format

WEST

Generate Collection

Search Results - Record(s) 1 through 2 of 2 returned.☐ 1. Document ID: WO 9835681 A1

L3: Entry 1 of 2

File: EPAB

Aug 20, 1998

PUB-NO: WO009835681A1

DOCUMENT-IDENTIFIER: WO 9835681 A1

TITLE: OXACARBAZEPINE FILM-COATED TABLETS

PUBN-DATE: August 20, 1998

INVENTOR-INFORMATION:

NAME

SCHLUETERMANN, BURKHARD

COUNTRY

DE

INT-CL (IPC): A61K 31/55; A61K 9/28

ABSTRACT:

CHG DATE=19990617 STATUS=O>The invention relates to formulations, e.g. film-coated tablets containing oxacarbazepine and to processes for the production of said formulations. The film-coated tablets have a tablet core comprising a therapeutically effective dose of oxacarbazepine being in a finely ground form having a mean particle size of from 4 to 12 μ m (median value), and a hydrophilic permeable outer coating.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	IMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-----------	-------

☐ 2. Document ID: NZ 336946 A, WO 9835681 A1, ZA 9801205 A, AU 9866222 A, NO 9903919 A, KR 98071337 A, CZ 9902879 A3, EP 966287 A1, BR 9807368 A, CN 1247471 A, SK 9901098 A3, JP 2000511935 W, HU 200000886 A2, MX 9907514 A1

L3: Entry 2 of 2

File: DWPI

Feb 23, 2001

DERWENT-ACC-NO: 1998-456864
DERWENT-WEEK: 200115
COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Tablets containing finely ground oxacarbazepine - for oral treatment of convulsions provide enhanced bioavailability and may be film coated

INVENTOR: SCHLUETERMANN, B; SCHLUETERMANN, B

PRIORITY-DATA: 1997CH-0000331 (February 14, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
NZ 336946 A	February 23, 2001	N/A	000	A61K009/14
WO 9835681 A1	August 20, 1998	E	021	A61K031/55
ZA 9801205 A	October 28, 1998	N/A	017	A61K000/00
AU 9866222 A	September 8, 1998	N/A	000	A61K031/55
NO 9903919 A	August 13, 1999	N/A	000	A61K031/55
KR 98071337 A	October 26, 1998	N/A	000	A61K009/28
CZ 9902879 A3	November 17, 1999	N/A	000	A61K031/55
EP 966287 A1	December 29, 1999	E	000	A61K031/55
BR 9807368 A	March 14, 2000	N/A	000	A61K031/55
CN 1247471 A	March 15, 2000	N/A	000	A61K031/55
SK 9901098 A3	March 13, 2000	N/A	000	A61K031/55
JP 2000511935 W	September 12, 2000	N/A	023	A61K031/55
HU 200000886 A2	September 28, 2000	N/A	000	A61K031/55
MX 9907514 A1	November 1, 1999	N/A	000	A61K031/55

INT-CL (IPC): A61K 0/00; A61K 9/14; A61K 9/28; A61K 31/55; A61P 25/08; C07D 0/00

ABSTRACTED-PUB-NO: WO 9835681A

BASIC-ABSTRACT:

Formulation (I) comprises oxacarbazepine (II) with a median particle size of 1-12 μ m, preferably 4-12 μ m, and more preferably 4-10 μ m, with a maximum residue on a 40 μ m sieve of at most 5%, e.g. 2%. Also claimed is (II) in the finely ground form specified above and film-coated tablets composed of it.

USE - (II) Is the agent of choice for the treatment of convulsions.

ADVANTAGE - (I) Provides a form of (II) which can be easily processed into dosage forms and which may increase bioavailability and patient compliance. Optionally tablets have hydrophilic permeable coatings.

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

KWIC	Draw Desc	Image
------	-----------	-------

Generate Collection